Precigen, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PGEN research report →
Range $12 – $18
Price Chart
About the company
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies.
- CEO
- Helen Sabzevari
- IPO
- 2013
- Employees
- 160
- HQ
- Germantown, MD, US
Get TickerSpark's AI analysis on PGEN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.51B
- P/E
- 62.52
- Fwd P/E
- 17.36
- PEG
- 0.40
- P/S
- 9.76
- P/B
- 18.26
- EV/EBITDA
- 39.50
- Div Yield
- 0.00%
- Gross Margin
- 91.01%
- Op Margin
- 21.43%
- Net Margin
- 15.55%
- ROE
- 57.93%
- ROIC
- 18.28%
Latest fiscal year · YoY change
- Revenue
- $9.68M+146.7%
- Gross Profit
- $3.59M+1149.1%
- Op Income
- $-106,600,000
- Net Income
- $-250,642,000-98.6%
- EPS
- $-1.41-200.0%
- OCF Growth
- -28.8%
- FCF Growth
- -17.0%
- 52W High
- $8.98
- 52W Low
- $3.04
- 50D MA
- $6.53
- 200D MA
- $5.27
- Beta
- 0.98
- RSI (14)
- 32
- Avg Volume
- 5.65M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Precigen posted a breakout third quarter driven by PAPZIMEOS launch momentum, with strong revenue growth, profitability, and positive operating cash flow ahead of guidance.· November 4, 2026
- Q3 net product revenue was $72.9 million from PAPZIMEOS; total revenue was $74.1 million.
- The company reported net income of $35.8 million in Q3 and positive operating cash flow of $11.9 million, ahead of prior guidance.
- Gross margin was 91%, with management saying U.S. PAPZIMEOS margins should stabilize in the high-80% to low-90% range.
- Management said more than 500 patients have started PAPZIMEOS and more than 300 have completed treatment, with broad adoption across disease severity.
- Precigen emphasized it is prepared for competition, with over 315 million covered lives, a permanent J-code, and established treatment-site infrastructure.
Precigen reported Q3 2026 total revenue of $74.1 million, including $72.9 million of PAPZIMEOS net product revenue. Q3 net income was $35.8 million, and net income for the 9-month period ended September 30, 2026 was $47.9 million. Cost of products and services was $6.5 million, producing gross margin of $67.6 million, or 91%. PAPZIMEOS revenue increased by approximately $20 million, or 37%, versus Q2. Cash and investments ended the quarter at $51 million, up from $38.7 million at the end of June, supported in part by $11.9 million in cash from operating activities. Management said gross margins on U.S. PAPZIMEOS sales should stabilize between the high-80% and low-90% range. They did not provide Q4 or full-year revenue guidance, but said they feel good about Q4 growth prospects and remain in expansion mode.
Helen Sabzevari framed the quarter as a major proof point for PAPZIMEOS and for Precigen’s broader platform. She emphasized the drug’s clinical differentiation, broad label, full FDA approval, and rapid commercial uptake, saying the company is building a durable first-mover advantage despite the recent competitor approval. Her tone was confident and strategic, with repeated focus on execution, leadership in RRP, and the potential to extend PAPZIMEOS into redosing, pediatrics, and global markets.
Harry Thomasian highlighted that PAPZIMEOS revenue drove profitability in both Q3 and the 9-month period, with Q3 net income of $35.8 million and 9-month net income of $47.9 million. He noted Q3 gross margin of 91%, R&D expense of $6.6 million versus $12.3 million in the prior-year quarter, SG&A of $22.4 million versus $24.0 million, and other expense net of $2.7 million, including about $3 million of interest expense on $100 million of debt. He also said cash and investments rose to $51 million, receivables were $96.5 million, and the company does not currently anticipate needing to raise additional capital, while noting another $25 million is available under the debt facility.
Analysts pressed on whether Q3’s growth rate is sustainable, the timing from prescription to first dose, hub conversion, and the impact of upcoming competition. Management said the key launch indicators remain positive, including hub activity, new account activation, and new patient starts, and described the prescription-to-treatment timeline as consistent with a normal rare-disease or oncology launch. On competition, they said they planned for it from the beginning and believe PAPZIMEOS will remain the preferred option due to efficacy, durability, safety, and ease of administration. They also said the European application is under review and that they are evaluating ex-U.S. partnership opportunities.
The bull case from this call is that PAPZIMEOS is showing sustained launch momentum, with Q3 revenue up 37% sequentially to $72.9 million and the company already profitable and cash-flow positive. Management believes the product’s 51% complete response rate, durability, broad label, and simple administration are supporting adoption across the full RRP patient spectrum and should help it hold share even as competition enters.
The main bear case is that the launch is entering a more competitive phase, with management acknowledging a new competitor and needing to defend momentum over the next few quarters. The call also offered no formal Q4 or full-year guidance, and several forward-looking comments depended on continued adoption, payer execution, and conversion of hub patients. International expansion, pediatric development, and redosing remain earlier-stage opportunities rather than current revenue drivers.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 45.9%
- Shares Outstanding
- 358.55M
- Float Shares
- 164.47M
of shares held by institutions
226 13F filers
Buy/sell ratio 0.54. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Patient Capital Management, LLC | 17.95M | ▼ 1.09M |
| Blackrock, Inc. | 17.28M | ▲ 133.62K |
| State Street Corp | 10.72M | ▼ 1.28M |
| Vanguard Group Inc | 10.48M | ▲ 1.54M |
| Vanguard Capital Management LLC | 8.01M | ▲ 104.87K |
| Tang Capital Management LLC | 6.42M | 0 |
| Geode Capital Management, LLC | 5.09M | ▲ 68.87K |
| Boxer Capital Management, LLC | 4.32M | ▼ 829.66K |
| Morgan Stanley | 4.13M | ▲ 662.09K |
| Diametric Capital, LP | 3.92M | ▼ 5.35M |
| Fmr LLC | 3.91M | ▲ 1.34M |
| Iridian Asset Management LLC/Ct | 3.06M | ▼ 967.39K |
Held by 249 ETFs
Biggest fund positions in PGEN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 23, 26 | Thomasian Harry Jr. | other | 1 |
| Sep 23, 26 | Thomasian Harry Jr. | other | 1 |
| Sep 23, 26 | Thomasian Harry Jr. | other | 2 |
| Sep 23, 26 | Thomasian Harry Jr. | other | 42,918 |
| Sep 23, 26 | Thomasian Harry Jr. | other | 10,744 |
| Sep 23, 26 | Thomasian Harry Jr. | other | 10,744 |
| Sep 23, 26 | Thomasian Harry Jr. | other | 42,918 |
| Sep 23, 26 | Thomasian Harry Jr. | other | 2 |
| Aug 26, 26 | KINDLER JEFFREY B | sell | 185,000 |
| Aug 21, 26 | AGEE NANCY H | buy | 3,411 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PGEN coverage
Recent articles, reports, and earnings notes.
No research on PGEN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PGEN report →Precigen: Upgrading To Buy As Competitive Fears Over VOCERYQ Look Overblown
seekingalpha.com · Nov 17
What Makes Precigen (PGEN) a New Buy Stock
zacks.com · Nov 9
PGEN Q3 Earnings Call Highlights Launch Momentum and Competition
zacks.com · Nov 9
Precigen, Inc. (PGEN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
What Precigen (PGEN) Said on Its Q3 Earnings Call
marketbeat.com · Nov 5
Precigen, Inc. (PGEN) Q3 Earnings and Revenues Miss Estimates
zacks.com · Nov 4
Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance
prnewswire.com · Nov 4
Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?
zacks.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.